90816-84-5

Upstream product

• 5460-29-7 2-(3-bromopropyl)isoindole-1,3-dione 
• 103-16-2 4-Benzyloxyphenol 
• 80199-92-4 1-benzyloxy-4-(3-bromopropoxy)benzene 
• 1074-82-4 potassium phtalimide 

Downstream Products

• 90816-85-6 N-<3-(4-hydroxyphenoxy)propyl>phthalimide 
• 100840-99-1 3-<4-(benzyloxy)phenoxy>propylamine 
• 100840-78-6 2-amino-6-({3-[4-(benzyloxy)phenoxy]propyl}amino)-5-nitroso-4(3H)-pyrimidinone 
• 104652-33-7 N-<3-<4-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyloxy)phenoxy>propyl>phthalimide 
• 104652-36-0 2-amino-6-<3-<4-(β-D-galactopyranosyloxy)phenoxy>propylamino>-5-nitrosopyrimidin-4(3H)-one 
• 104652-32-6 Acetic acid 4-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propoxy]-phenyl ester 
• 104652-35-9 3-<4-(β-D-galactopyranosyloxy)phenoxy>propylamine 

Relevant academic research and scientific papers

COMPOUNDS WITH COMBINED CALCIUM CHANNEL BLOCKER AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITIES FOR TREATMENT OF HEART DISEASE

The present invention provides compounds possessing inhibitory activity against β-adrenergic receptors and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds, methods of preparing such compounds, and methods of using such compounds for regulating calcium homeostasis, for treating a disease, disorder or condition in which disregulation of calcium homeostasis is implicated, and for treating hypertension, cardiovascular disease, congestive heart failure, myocardial ischemia, cardiomyopathies, stroke or epilepsy.

COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE

This invention provides compounds that possess inhibitory activity against β--adrenergic receptors and phosphodiesterase PDE, including phosphodiesterase 3 (PDE3 ). This invention further provides pharmaceutical compositions comprising such -compounds; methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine; and methods of preparing pharmaceutical compositions and compounds that possess inhibitory activity against ?-adrenergic receptors and PDE.

Therapeutic amines

Compounds of formula I, and their pharmaceutically acceptable salts, STR1 in which R1 and R2 are hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenylalkyl or alkenyl; or NR1 R2 is a heterocyclic group; A is trimethylene optionally substituted by alkyl and the phenyl ring is optionally substituted by substituents such as halogeno, alkenyl, amino, cyano, ureido, alkyl, carbamoylalkyl, alkanoylamino, alkoxycarbonyl, N-alkyl-alkanoylamino, alkanoyl and amines thereof; are inhibitors of squalene synthese and hence useful in treating diseases in which a lowering of cholesterol is desirable. As well as the use of these compounds in medicine, novel compounds, processes for their preparation and pharmaceutical compositions are also referred to.

Substituted (10H-phenothiazin-10-L)-propyl-1-piperazines

Substituted (10H-phenothiazin-10-yl)propyl-1-piperazines of the formula STR1 wherein R1, R2, R3, A, X, m, n and s are as hereinafter set forth, are described. The compounds of formula I, which contain a piperazine moiety combined by an ether linkage to different phenolic moieties, are useful as orally active long lasting antipsychotic agents.